Table 3 Patients with SD ≥ 24 weeks, CR or PR by RECIST v1.1
From: Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations
Subject ID | Cancer Type | Cohort Assignment | Cohort Specific Molecular Alteration | Best Response by RECIST v1.1 | # of Prior Systemic Therapies | Duration of Treatment (weeks) | Response length (weeks) |
|---|---|---|---|---|---|---|---|
01-040 | Leiomyosarcoma of uterus | 1 | BRCA2 S2186fs*3 | −1% (SD) | 4 | 32 | 24.1 |
01-048 | Soft tissue sarcoma | 1 | BRCA1 V788fs*10 | −54% (PR) | 6 | 23 | 7.4 |
01-061 | Ovarian | 1 | BRCA2 R3052W | −100% (CR) | 3 | 182+ | 31+ |
01-073 | Breast | 1 | BRCA1 Q356* | −14% (SD) | 7 | 40 | 32.6 |
01-079 | Salivary Gland | 1 | BRCA1_M1I | −73% (PR) | 2 | 31 | 23.4 |
01-082 | Breast Cancer | 1 | BRCA1_Q380* | −81% (PR) | 3 | 112+ | 88.6+ |
02-054 | Appendiceal | 2 | ATM S1599* | −33% (PR) | 2 | 61 | 12 |
02-007 | Ovarian | 2 | BRIP1 (FANCJ) A402Vfs*21 | 3% (SD) | 4 | 34 | 26.1 |
02-032 | Cholangiocarcinoma | 2 | ATM_ G1676fs | −38% (PR) | 2 | 60 | 16 |
02-033 | Myoxid Spindle Cell sarcoma | 2 | FANCC Loss of exon 28 | −10% (SD) | 3 | 25 | 24.6 |
02-035 | Urachal adenocarcinoma | 2 | PALB2 R170fs14 | −35% (PR) | 3 | 25 | 17 |
02-062 | GE Junction | 2 | ATM deletion ATM E2052* | 8% (SD) | 3 | 31 | 24 |
03-008 | Gallbladder | 3 | PTEN L70F | 5% (SD) | 6 | 32 | 24 |
04-034 | Cholangiocarcinoma | 4 | BRCA2 2041insA | −14% (SD) | 6 | 34 | 25.7 |
04-029 | Ampulla of Vater | 4 | BRCA2_c.8633-1 G > C | −20% (SD) | 2 | 124 | 116.3 |
04-052 | Adenocarcinoma of cecum | 4 | BRCA2 p.K944* | −100% (PR)a | 2 | 62 | 25.1 |
04-065 | Gastric adenocarcinoma | 4 | BRCA2 c.7878 G > A p.Trp2628Ter | −11% (SD) | 4 | 87 | 81 |
04-075 | Pancreatic | 4 | BRCA 2 D252Vfs*24 | −11% (SD) | 4 | 44 | 36.4 |
